Coronavirus company news summary – NeuroRx, Relief and Quantum Leap team up on I-SPY Covid-19 trial – Indonesia approves Sinovac’s Covid-19 vaccine

12 January 2021 (Last Updated January 12th, 2021 08:44)

12 January 2021 

NeuroRx, Relief Therapeutics and the Quantum Leap Healthcare Collaborative announced a partnership agreement for the inclusion of ZYESAMI in the I-SPY Covid-19 clinical trial.  The I-SPY Covid-19 trial assesses various drugs for treating critical Covid-19 patients who are hospitalised or in intensive care units; the trial is being sponsored by Quantum Leap.

DalCor announced the launch of dal-COVID, a Phase II proof-of-concept study for Dalcetrapib as an oral anti-viral treatment for Covid-19. Dalcetrapib binds to the catalytic site of 3CLMpro of the SARS-CoV-2 virus, thereby impeding its activity and viral reproduction. dal-COVID is a double-blind, placebo-controlled trial to be conducted in mild to moderate symptomatic Covid-19 patients.

Dr Reddy’s Laboratories announced that an ongoing Phase II trial of the Russian Covid-19 vaccine, Sputnik V, has been reviewed by its independent Data and Safety Monitoring Board (DSMB). The DSMB found that Sputnik V met the primary endpoint of safety and recommended submitting the data to regulators to decide on advancing to Phase III trials.

Indonesia’s food and drug authority (FDA) granted emergency use authorisation to Chinese Sinovac Biotech’s Covid-19 vaccine, thereby becoming the first country outside China to give regulatory approval to the vaccine, as reported by Reuters. According to Penny K Lukito, who heads the country’s FDA, interim data from a late-stage clinical trial in Indonesia found the vaccine to be 65.3% effective.